CLEO Diagnostics Ltd (ASX:COV) has gained ground with investors in 2026 as the medical-technology company advances a blood test aimed at improving the detection of ovarian cancer. The Australian-listed diagnostics developer has drawn attention from healthcare investors after clearing a key clinical milestone in the United States, a market central to its commercial ambitions. With a regulatory pathway taking shape, CLEO has become one of the more talked-about small-cap ASX healthcare shares in September 2026.

Latest Developments

CLEO's pivotal development in 2026 was completing a major US clinical-trial milestone. In late March 2026, the company reported that it had enrolled 624 women across 19 specialised US sites and secured 514 blood samples, exceeding its minimum target of 500. That data provides the primary clinical evidence required to support an FDA 510(k) submission, the regulatory route used for many diagnostic devices in the United States. The company has also partnered with a CLIA-certified laboratory, Asuragen, for key US clinical validation work, and progressed Manufacturing arrangements, with test-kit production agreements advancing following biomarker panel optimisation reported earlier in the year. Each of these steps moves CLEO closer to the point at which it can formally lodge its submission with the regulator.

What Could Come Next

The near-term focus is on analytical validation, clinical sample testing, and statistical analysis of the test's sensitivity and specificity against surgical pathology confirmation, followed by the FDA 510(k) submission. Progress toward that submission, and ultimately any regulatory clearance, would be significant catalysts for the stock. Finalising binding manufacturing agreements for test-kit production would also support a smoother path to commercialisation should approval follow.

Risks to Watch

CLEO remains a pre-revenue company dependent on regulatory success. FDA clearance is not guaranteed, and timelines can extend. Clinical and analytical validation must confirm the test's performance before approval. As a development-stage business, CLEO may need to raise further capital, introducing dilution risk. Small-cap healthcare shares are typically volatile and can move sharply on trial or regulatory news.

Conclusion

CLEO Diagnostics has moved through a meaningful clinical milestone in 2026, strengthening the case for its ovarian-cancer blood test as it targets a US regulatory submission. The Investment story now depends on validation data and FDA progress rather than near-term revenue. For investors following speculative healthcare ASX shares in September 2026, CLEO's regulatory journey and the potential size of its addressable market will be closely watched.